Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Abstract
Over the last decade, the discovery of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) has increased the treatment options for patients with type 2 diabetes mellitus (T2DM). GLP-1 RAs mimic the effects of native GLP-1, which increases insulin secretion, inhibits glucagon secretion, increases satiety and slows gastric emptying. This review evaluates the phase III trials for all approved GLP-1 RAs and reports that all GLP-1 RAs decrease HbA1c, fasting plasma glucose, and lead to a reduction in body weight in the majority of trials. The most common adverse events are nausea and other gastrointestinal discomfort, while hypoglycaemia is rarely reported when GLP-1 RAs not are combined with sulfonylurea or insulin. Treatment options in the near future will include co-formulations of basal insulin and a GLP-1 RA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DUL is a long-acting GLP-1R agonist which can promote insulin secretion, inhibit gastric emptying, and reduce appetite. It is approved for treating hyperglycemia in patients with T2DM in many countries (105, 106).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [106]
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“reported significantly decreased postprandial plasma glucose (PPG) levels in the 5 and 10 μg exenatide groups compared with the placebo group.[15,16] In patients of Asian descent treated with oral antidiabetic agents, Gao et al.”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 1×
“respectively, and minor hypoglycemic events were less frequent in the liraglutide group than in the exenatide group.[103]”
BackgroundBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · cited 6×
“[103] The DURATION-6 trial investigated EQW 2 mg headto-head with liraglutide 1.8 mg QD in patients treated with metformin, SU, TZD or a combination of these drugs for 26 weeks (baseline HbA1c 8.4–8.5%; BMI 32.3 kg/m2).”
BackgroundInfluentialGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 11×
“Meanwhile, the longer half-lives of the longer-acting GLP-1 RAs allow for greater effects on the total 24 h glucose level, including FPG.[6] This difference found among GLP-1 RAs is also evident in their varying efficacies with regard to HbA1c reduction and weight loss, as well as their differing tolerability profiles…”
BackgroundInfluentialKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 8×
“[103] The DURATION-6 trial investigated EQW 2 mg headto-head with liraglutide 1.8 mg QD in patients treated with metformin, SU, TZD or a combination of these drugs for 26 weeks (baseline HbA1c 8.4–8.5%; BMI 32.3 kg/m2).”
BackgroundInfluentialNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 3×
“Drucker, 2008 [72] Exenatide 2 mg QW 295 30 Met/SU/TZD or a combination −1.”
BackgroundResultGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · cited 2×
“5%).[49,50,55] The LEAD-1 trial found liraglutide 1.”
ResultVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 1×
“treatment period of 20 weeks.[12] Exenatide BID is subcutaneously administered before the morning and evening meals as 5 μg BID for the first four weeks of”
Method
Research works printed but not linked: 8
- American Diabetes Association, 2015, Diabetes Care, 38
- Lund A, 2014, Eur J Intern Med
- Robinson LE, 2013, BMJ Open, 3
- Mann KV, 2014, Diabetes Metab Syndr Obes Targets Ther, 7, 229
- Woodward HN, 2014, Patient Prefer Adherence, 8, 789
- Blair HA, 2015, Drugs
- 10.2337/dc09-0366 · DOI · Paper page
- Giorgino F, 2015, Diabetes Care
Cited by
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Mitchell, P. D., Salter, B. M., Oliveria, J. P., El‐Gammal, A., Tworek, D., Smith, S. G., Sehmi, R., Gauvreau, G. M., Butler, M., & O'Byrne, P. M. (2017) · Clinical & Experimental Allergy · doi:10.1111/cea.12860 · Cited by 78
Huang, S., Ma, S.-Y., Ning, M., Yang, W., Ye, Y., Zhang, L., Shen, J., & Leng, Y. (2019) · Metabolism · doi:10.1016/j.metabol.2019.07.003 · Cited by 65
Discovery of ecnoglutide - a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog
Guo, W., Xu, Z., Zou, H., Li, F., Li, Y., Feng, J., Zhu, Z., Zheng, Q., Zhu, R., Wang, B., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101762 · Cited by 58
“In the last few years, dulaglutide and semaglutide have become available; these are long-acting GLP-1 analogs with >100hour half-lives and require once weekly injection [3,4].”
BackgroundWang, Q., Wang, J., Li, N., Liu, J., Zhou, J., Zhuang, P., & Chen, H. (2022) · Molecules · doi:10.3390/molecules27020444 · Cited by 63
Metadata
- Authors
- Østergaard, L., Frandsen, C. S., & Madsbad, S.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Østergaard, L.
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2016-01-08
- Volume
- 9
- Issue
- 2
- Pages
- 241-265
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W2220690107
- Cited by
- 38
- References
- 134
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 1 · 2023: 4 · 2022: 3 · 2020: 3 · 2019: 4 · 2018: 2 · 2017: 7 · 2016: 5
- FWCI
- 0.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, glucagon-like peptide-1, insulin secretion, glucagon inhibition, satiety, gastric emptying, HbA1c reduction, fasting blood glucose, weight loss, nausea, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Insulin Secretion, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon, Humans, Hypoglycemic Agents, Insulin, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. https://app.cochat.ai/papers/10.1586/17512433.2016.1121808
- The paper
- Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016). Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. Expert Review of Clinical Pharmacology. https://doi.org/10.1586/17512433.2016.1121808
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.